RGNX compared with FATE: revenue, margins and what each company keeps, and the suppliers and customers both name

RGNXRegenxbio Inc.

Mkt capRevenueRevenue

FATEFate Therapeutics Inc

Mkt capRevenueRevenue

Compare

RGNXRegenxbio Inc.

FATEFate Therapeutics Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

RGNX

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±18.2%▲+7.43%×0.41

May 14 '26±32.5%▼−37.80%×1.16

Q1 FY26±42.1%▼−4.60%×0.11

Q3 FY25±16.9%▼−3.79%×0.22

FATE

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±20.5%▼−7.35%×0.36

May 13 '26±57.5%▼−5.11%×0.09

= impliedRGNX realized, solidFATE realized, hatchedOne scale, both sides: full bar = 58%× = |realized| ÷ impliedSource: market data

Q1 FY26

±21.3%

▲+5.41%

×0.25

Q3 FY25±14.5%▼−4.59%×0.32

RGNXRegenxbio Inc.

7.19▼−0.20%· delayed

Mkt cap$475.3MRevenue$108MQ2 FY26Revenue$170MFY25

FATEFate Therapeutics Inc

2.03▼−2.40%· post 2.03· delayed

After hoursNov 2 '26delayed

Mkt cap$249.2MRevenue$2MQ2 FY26Revenue$7MFY25

Compare

After hoursNov 2 '26delayed

RGNXRegenxbio Inc.

FATEFate Therapeutics Inc

7.19▼−0.20%delayed

Price

2.03▼−2.40%post 2.03delayed

$475.3M

Mkt cap

$249.2M

Q2 FY26$108M

Revenue

$2MQ2 FY26

FY25$170M

Revenue

$7MFY25

RGNX7.19▼−0.20%vsFATE2.03▼−2.40%After hoursNov 2 '26delayed